Exploring a New Combination Therapy to Prevent Renal Cell Cancer Recurrence
Immune checkpoint inhibitors have transformed the management of patients with advanced kidney cancer. However, these therapies only work for a subset of patients with advanced disease and can be associated with substantial side effects. As a result, researchers are focused on new therapeutic combinations to boost the effectiveness of current immune therapies in renal cancer, including in patient populations with early-stage disease that is likely to recur.